We are live on ! Find out more
FBIOP icon

Fortress Biotech 9.375% Series A Preferred Stock
FBIOP

1 hedge funds and large institutions have $1.37M invested in Fortress Biotech 9.375% Series A Preferred Stock in 2022 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

4.95% less ownership

Funds ownership: 7.14% → 2.19% (-5%)

67% less funds holding

Funds holding: 3 → 1 (-2)

77% less capital invested

Capital invested by funds: $5.87M → $1.37M (-$4.5M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-2
Holders Change %
-66.67%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
UIC
Uniplan Investment Counsel
Wisconsin
-$3.58M
2
SAM
Shikiar Asset Management
New York
-$424K
3
PCG
Private Capital Group
Connecticut
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
1
Shikiar Asset Management
New York
$1.37M -$424K -20,460 -21%
UIC
2
Uniplan Investment Counsel
Wisconsin
– -$3.58M -149,327 Closed
PCG
3
Private Capital Group
Connecticut
– -$3K -135 Closed

FBIOP Hedge Fund Activity: Q2 2022 in Review

1 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) for Q2 2022, worth a combined $1.37M — down 77% from $5.87M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of FBIOP and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Uniplan Investment Counsel, exiting entirely with an estimated $3.58M sold.

  • 1 institutional investor held Fortress Biotech 9.375% Series A Preferred Stock (FBIOP) as of Q2 2022, down from 3 in Q1 2022.
  • Funds reported $1.37M of Fortress Biotech 9.375% Series A Preferred Stock stock for Q2 2022, down 77% quarter-over-quarter.
  • 0 funds opened new Fortress Biotech 9.375% Series A Preferred Stock positions in Q2 2022 and 2 closed out, a net change of -2 holders.
  • The largest Fortress Biotech 9.375% Series A Preferred Stock seller in Q2 2022 was Uniplan Investment Counsel, an estimated $3.58M sold.

Based on aggregated 13F filings for Q2 2022.